TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03574415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP14012 placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP14012 placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP14012 placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP14012 placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP14012 placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP14012 placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP14012 placebo-matching tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: DWP14012 placebo-matching tablets
Study: NCT04384432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physical Therapy with Thoracic mobility exercise
Description: Combınatıon of routıne Routine Physical Therapy with Thoracic mobility exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routıne Physıcal therapy
Description: Exercise for Chronic Neck Pain
Study: NCT01946412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Study: NCT01560611

Intervention type: DEVICE
Intervention: Near infrared spectroscopy
Study: NCT00222417

Intervention type: PROCEDURE
Intervention: myringoplasty
Description: Myringoplasty is an operative procedure to close tympanic membrane perforations.

Intervention type: PROCEDURE
Intervention: Stapes surgery
Description: Operative procedure aimed to replace non-functioning stapes with a synthetic prosthesis
Study: NCT02670928

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention
Description: Patients of active group were assigned to receive activities of the program for life style changes. Patients in control group were managed in frames of routine clinical practice. No any investigational drug therapy was used.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Patients of active group were assigned to receive activities of the program for life style changes. Patients in control group were managed in frames of routine clinical practice. No any investigational drug therapy was used.
Study: NCT01802099

Intervention type: OTHER
Group type: OTHER
Intervention: Enteral nutrition

Intervention type: OTHER
Group type: OTHER
Intervention: Parenteral nutrition
Study: NCT00689897

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture, Deqi
Description: Immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the DeQi sensation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture, Non-Deqi
Description: After insertion of a needle, no manipulation is applied, and the needle is retained for 30 minutes.
Study: NCT01616277

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PF-06252616
Description: 1.0 milligram per kilogram of PF-06252616, IV infusion, single dose
Study: NCT01954888

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blind technique
Description: A mixture of 3 mL of 2% lidocaine and 7 mL of 0.5% bupivacaine is used for both approaches (blind and ultrasound-guided).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided technique
Description: A mixture of 3 mL of 2% lidocaine and 7 mL of 0.5% bupivacaine is used for both approach (blind and ultrasound-guided).
Study: NCT00781963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manual-based cognitive behavioral therapy for insomnia
Description: Manual-based CBT-I provided in 5 individual or group sessions by a non-clinician sleep coach.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-directive sleep education
Description: Manual-based non-directive sleep education provided in 5 group sessions by a health educator.
Study: NCT04446871

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: Intravenous infusion of 500 cc of 0.9% sodium chloride solution for 6 h, once a day for a total of 3 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Intravenous infusion of 100 mg methylene blue in 500 cc of 0.9% sodium chloride solution for 6 h, once a day for a total of 3 doses.
Study: NCT01768312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine ophthalmic solution
Description: 1 drop twice/day for 12 weeks to both eyes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine ophthalmic solution
Description: 1 drop twice/day for 12 weeks to both eyes
Study: NCT05382988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate
Description: The experimental group was required to take SZC 10g at 6 am on the day of surgery.
Study: NCT00654953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline
Description: Sertraline hydrochloride (200 mg/day) will be administered once daily. While subjects are at RCA-NLR they initially receive 50 mg/day of sertraline. This dose is gradually increased over a 3-week period until subjects receive 200 mg. When subjects are transferred to the outpatient program, they will be administered capsules once weekly, with take-home doses given in blister packs to take once a day for the rest of the week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline
Description: Sertraline hydrochloride (200 mg/day) will be administered once daily. While subjects are at RCA-NLR they initially receive 50 mg/day of sertraline. This dose is gradually increased over a 3-week period until subjects receive 200 mg. When subjects are transferred to the outpatient program, they will be administered capsules once weekly, with take-home doses given in blister packs to take once a day for the rest of the week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (cellulose or lactose) administered twice per day for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (cellulose or lactose) administered twice per day for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin
Description: Gabapentin (Neurontin; Parke-Davis; 1200 mg/day) will be administered twice daily. Initially, patients will receive 200 mg twice daily on days 1-5, 400 mg twice daily on days 6-10, then 600 mg twice daily on days 11 on. Subjects are then maintained on this dose for the duration of the trial, unless side-effects are too severe, in which case the dose of gabapentin is decreased to no less 800 mg/day. If symptoms persist, subjects' participation would then be terminated.
Study: NCT00546234

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Description: 18 mcg daily via Handihaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: long acting beta agonist
Description: Turbohaler, 6 \& 12 mcg
Study: NCT01683084

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04438772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Check the condition of intubation with LPEC compared with a sham procedure in the general anesthesia
Description: Intubation with Left Paratracheal Esophagus Compression (LPEC) or sham procedure and evaluation of intubation's condition

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Check the condition of intubation with LPEC compared with a sham procedure in the general anesthesia
Description: Intubation with Left Paratracheal Esophagus Compression (LPEC) or sham procedure and evaluation of intubation's condition
Study: NCT03289871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excilor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loceryl 5%
Study: NCT01679561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intralipid
Description: intravenous intralipid 20% is given to the patients known to be have either recurrent failed IVF, RPL
Study: NCT04201938

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Symbiter-Omega
Description: Symbiter-Omega contains combination of flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5%), supplemented with biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00525239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, efavirenz
Description: 100 mg, twice daily, for four weeks
Study: NCT01319019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081
Description: Comparison of different doses and dosing regimens of the drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081
Description: Comparison of different doses and dosing regimens of the drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081
Description: Comparison of different doses and dosing regimens of the drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081
Description: Comparison of different doses and dosing regimens of the drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081
Description: Comparison of different doses and dosing regimens of the drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081
Description: Comparison of different doses and dosing regimens of the drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Positive control

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm
Study: NCT00745381

Intervention type: OTHER
Intervention: questionnaire, Blood specimens
Description: All participants will complete an epidemiology study questionnaire as well as a quality of life questionnaire. They will also be asked to donate blood samples. We will request participation in a tissue repository consisting of fresh frozen or paraffin embedded tissue. The repository will be of serum, plasma and tumor tissue. Follow-up will occur on patients every 6 months for the first year after consent and then annually.
Study: NCT02064205

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 12.5 g polydextrose
Description: Appetite suppressing supplement is added in yogurt and provided with breakfast (four hours before lunch) or 1.5h before lunch. Also yogurt with control (glucose syrup) is tested for its satiating effect.
Study: NCT01616277

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for PF-06252616, IV infusion, single dose
Study: NCT02064205

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 12.5 g polydextrose
Description: Appetite suppressing supplement is added in yogurt and provided with breakfast (four hours before lunch) or 1.5h before lunch. Also yogurt with control (glucose syrup) is tested for its satiating effect.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: glucose syrup
Description: Glucose syrup is used a control product for the polydextrose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: glucose syrup
Description: Glucose syrup is used a control product for the polydextrose
Study: NCT02176304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depomedrol
Description: Depomedrol 40 mg/ml, 1 ml injected to knee on day one of intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depomedrol
Description: Depomedrol 40 mg/ml, 1 ml injected to knee on day one of intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine 2% soln, 4 ml injected to knee on day 1 of intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine 2% soln, 4 ml injected to knee on day 1 of intervention
Study: NCT01616277

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PF-06252616
Description: 3.0 milligram per kilogram of PF-06252616, IV infusion, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for PF-06252616, IV infusion, single dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PF-06252161
Description: 10.0 milligram per kilogram of PF-06252616, IV infusion, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for PF-06252616, IV infusion, single dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PF-06252616
Description: 3.0 milligram per kilogram of PF-06252616, Subcutaneous injection, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for PF-06252616, Subcutaneous injection, single dose
Study: NCT03928860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OMT session
Description: Patients with PAD will be received 30 minutes of osteopathic manual treatment for one session. During application, the patient was in the supine position. OMT treatment session include, sub occipital release technique, supraclavicular release technique, sternal mobilization, omentum minus release, liver pumping, diaphragmatic mobilization, grand manevra technique, hip mobilization, knee mobilization and ankle mobilization. Each technique was applied for 3 minutes to patients.
Study: NCT00925145

Intervention type: PROCEDURE
Intervention: Single Incision Laparoscopic Appendectomy
Study: NCT03770195

Intervention type: DEVICE
Intervention: HEMOBLAST Bellows
Description: The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
Study: NCT01646801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMB Balloon Catheter
Description: patients treated by the NMB's Drug Ejecting Balloon
Study: NCT01877590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid
Study: NCT01226706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxins, Type A
Description: Botulinum Toxins, Type A 100U injected into the detrusor at Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos injected into the detrusor at Day 1, followed by injection of botulinum toxin Type A 100U after 24 weeks has elapsed from previous treatment, if requested/qualified.
Study: NCT01165099

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: The description of the acupuncture, whether manual, electro or sham, is as described for each of the individual groups.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: The description of the acupuncture, whether manual, electro or sham, is as described for each of the individual groups.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: The description of the acupuncture, whether manual, electro or sham, is as described for each of the individual groups.
Study: NCT02317341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single intravenous dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (saline)
Description: Given intravenously over 40 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (saline)
Description: Given intravenously over 40 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single intravenous dose given over 40 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Given intravenously over 40 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam(placebo)
Description: Given intravenously over 40 minutes
Study: NCT00759746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SFM+ Low Dose
Description: The SFM intervention assumes people need a social environment that supports changes in eating and physical activity for continued weight maintenance. Therefore, the SFM intervention will focus on helping families create a social environment that supports weight maintenance (e.g., children being friends with physically active peers). Participants in this group will meet less often than families that receive the Social Facilitation Maintenance (SFM) - High Dose intervention, giving them more opportunities to practice new skills between clinic visits.
Study: NCT02472171

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High saturated fat meal, placebo powder and sunflower oil
Description: High saturated fat meal with a blueberry flavored shake and sunflower oil
Study: NCT00759746

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Maintenance Education
Description: The Weight Maintenance Education intervention will help participants in parent and child groups to learn more about healthy eating and physical activity in a group setting. Participants will also learn about exercise and exercise safety, hydration during exercise, and stress management. Parent and child groups will combine for particular on-site and off-site activities, such as cooking demonstrations, grocery store tours, gym tours, and dance lessons.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SFM+ High Dose
Description: The SFM intervention assumes people need a social environment that supports changes in eating and physical activity for continued weight maintenance. Therefore, the SFM intervention will focus on helping families create a social environment that supports weight maintenance (e.g., children being friends with physically active peers). Participants in this group will meet more often than families that receive the Social Facilitation Maintenance (SFM) - Low Dose intervention, allowing for more in-depth discussion and practice of key skills and concepts related to creating a social environment that supports a healthy lifestyle. These participants will receive more feedback and reinforcement from fellow group members, family interventionists, and group leaders for practicing their new behaviors.
Study: NCT03385174

Intervention type: OTHER
Group type: OTHER
Intervention: Carbon monoxide
Description: Carbon monoxide inhalation
Study: NCT02472171

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High saturated fat meal, placebo powder and sunflower oil
Description: High saturated fat meal with a blueberry flavored shake and sunflower oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High saturated fat meal, placebo powder and sunflower oil
Description: High saturated fat meal with a blueberry flavored shake and sunflower oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High saturated fat meal, placebo powder and sunflower oil
Description: High saturated fat meal with a blueberry flavored shake and sunflower oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High saturated fat meal, placebo powder and sunflower oil
Description: High saturated fat meal with a blueberry flavored shake and sunflower oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High saturated fat meal, placebo powder and sunflower oil
Description: High saturated fat meal with a blueberry flavored shake and sunflower oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High saturated fat meal, blueberry powder and sunflower oil
Description: High saturated fat meal with blueberry powder shake and sunflower oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High saturated fat meal, blueberry powder and sunflower oil
Description: High saturated fat meal with blueberry powder shake and sunflower oil
Study: NCT02808351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Study: NCT01514149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJC-1134-PC Injection
Description: CJC-1134-PC administered weekly by subcutaneous injection
Study: NCT03025893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib, 300 mg administered orally in a weekly schedule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine
Description: Lomustine 110 mg/m2, taken orally on day 1 every 6 weeks.
Study: NCT01949298

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dental implant placement